Patents Assigned to Japan Stent Technology Co., Ltd.
-
Patent number: 9040111Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.Type: GrantFiled: December 28, 2012Date of Patent: May 26, 2015Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8968392Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: GrantFiled: July 30, 2012Date of Patent: March 3, 2015Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo IwataInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8882827Abstract: The stent comprises a tubular body comprising a plurality of ring units arranged in the axis direction and bridged by a connecting element. Each of the units comprises a plurality of cells connected with each other, each of the cells having a U-shaped form comprising two linear parts and a circular arc part therebetween, and opening toward one end. The ring units comprise first and second units alternatively arranged and the oppositely disposed cells of the first and second units are only partly bridged by the connecting elements. The shapes of the cells of the first and second units are axisymmetrical about the connecting element. The curvature radius of the top of the arc constituting the arc part is 1.1 and 1.5 times larger than that of each of the tangent circles formed at the edges of two linear parts of the cell on the circular arc part side.Type: GrantFiled: September 16, 2010Date of Patent: November 11, 2014Assignee: Japan Stent Technology Co., Ltd.Inventors: Hai Quan Feng, Suguru Kishimoto, Jun Kubota, Minoru Asahara
-
Patent number: 8652199Abstract: To provide a stent which holds various performances such as deliverability, prevention of restenosis, flexible shape conformability, and so on and is therefore adaptable not only to a bile duct but also to a blood vessel system such as a tortuous coronary artery substantially without causing restenosis. A stent with an autonomic function is made of a Ti—Ni based shape memory alloy and has a maximum expanding force at a center portion in its lengthwise direction.Type: GrantFiled: May 23, 2006Date of Patent: February 18, 2014Assignees: NEC Tokin Corporation, Tohoku University, Japan Stent Technology Co., Ltd.Inventors: Michihide Ozawa, Kiyoshi Yamauchi, Yuji Sutou, Takamitsu Takagi, Shuzou Yamashita, Kouji Mori
-
Patent number: 8641756Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: June 8, 2012Date of Patent: February 4, 2014Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata Institute for Frontier Medical Sciences, Kyoto UniversityInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8591782Abstract: A stent comprising a tubular stent matrix of which diameter is extendable and a flexible polymer layer covering the stent matrix. The polymer layer is closely attached to and covers the entire surface of the stent matrix. Since the flexible polymer layer closely covers the entire surface of the stent matrix not only the outer periphery of the stent matrix, the stent has no problem of causing allergic to metal, stimulus of tissues due to metal, and rust development. Since the inner periphery of the stent is a flat and smooth surface covered by the polymer layer without convexes and concaves, the formation of thrombus can be inhibited well. There is no problem of drift between the polymer layer and the stent matrix, thereby maintaining the positional relationship between the stent matrix and the polymer layer before and after the expansion of the stent.Type: GrantFiled: August 20, 2003Date of Patent: November 26, 2013Assignees: National Cerebral and Cardiovascular Center, Japan Stent Technology Co., Ltd.Inventors: Yasuhide Nakayama, Shogo Nishi, Yasushi Nemoto, Yoshihiro Okamoto
-
Patent number: 8591571Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).Type: GrantFiled: August 25, 2011Date of Patent: November 26, 2013Assignee: Japan Stent Technology Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin
-
Patent number: 8435287Abstract: A stent includes a tubular stent body 11, a diamond-like carbon film 12 formed on the surface of the stent body 11 and having an activated surface, and a polymer layer 13 immobilized on the surface of the diamond-like carbon film. The polymer layer 13 contains a drug 14 having an effect to prevent restenosis, and the drug 14 is gradually released from the polymer layer 13.Type: GrantFiled: January 15, 2007Date of Patent: May 7, 2013Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., LtdInventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Ikuo Komura, Koji Mori
-
Patent number: 8409272Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: September 3, 2008Date of Patent: April 2, 2013Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20130018455Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: ApplicationFiled: July 30, 2012Publication date: January 17, 2013Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20120310329Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: June 8, 2012Publication date: December 6, 2012Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo OMURA, Zhen Yu JIN, Shuzo YAMASHITA, Hiroo IWATA, Akira MOCHIZUKI
-
Publication number: 20110313514Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).Type: ApplicationFiled: August 25, 2011Publication date: December 22, 2011Applicant: JAPAN STENT TECHNOLOGY CO., LTD.Inventors: Ikuo Omura, Zhen Yu Jin
-
Patent number: 7931934Abstract: A medical device includes a medial device body, and a diamond-like thin film covering the medical device body and containing silicon. The diamond-like thin film has a concentration of silicon which is lower in a surface thereof than in an interface thereof with the medical device body mentioned above, and continuously varies.Type: GrantFiled: January 15, 2007Date of Patent: April 26, 2011Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., Ltd.Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Koji Mori, Ikuo Komura
-
Publication number: 20100198344Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: September 3, 2008Publication date: August 5, 2010Applicants: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 7658761Abstract: A balloon expandable superelastic stent is made of a Ti—Ni—Nb (the content of Nb being at least 3 at %) shape memory alloy. A shape recovery temperature of the stent is lower than a living body temperature in an unloaded state after shape memory treatment. The shape recovery temperature exceeds the living body temperature after the stent is mounted to a catheter and released from the catheter in a living body.Type: GrantFiled: March 3, 2005Date of Patent: February 9, 2010Assignees: NEC Tokin Corporation, Japan Stent Technology Co., Ltd.Inventors: Kiyoshi Yamauchi, Kouji Mori, Shuzou Yamashita
-
Publication number: 20090131271Abstract: In a method for delivering a nucleic acid of the invention, a nucleic acid is introduced into a cell by pressing the nucleic acid supported on a surface of a solid substrate against the cell. According to the method, the nucleic acid can be delivered into the cell simply at a low cost without placing a heavy burden on the cell at a high nucleic acid delivery efficiency. By allowing the surface of the solid substrate to support the nucleic acid in the form of a complex with a polyamine or a cationic lipid and pressing it against the cell, the introduction efficiency into the cell can be further improved. In the invention, by using a nucleic acid useful for gene therapy as the nucleic acid, a high-efficiency device for gene therapy can be obtained.Type: ApplicationFiled: May 16, 2006Publication date: May 21, 2009Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, JAPAN STENT TECHNOLOGY CO, LTD.Inventors: Takuro Niidome, Fumio Wada, Yoshiki Katayama, Kosuke Yakumaru, Takahito Kawano, Shuzo Yamashita
-
Publication number: 20090048667Abstract: A drug-releasable medical device contains a controlled drug-release composition comprising 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a lipid-soluble, low molecular weight release auxiliary agent and 1 to 70 parts by weight of a drug. When the composition is applied on a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, the medical device is provided with a drug release function. Argatroban or sarpogrelate hydrochloride or both of them are gradually released from the surface of a stent for treating coronary artery stenosis, for example. In order to exhibit a sustained-release function for a desired period of time, the drug to be gradually released is carried in a polymeric material coated on a surface of a metal forming the stent or in a porous stent substrate.Type: ApplicationFiled: November 15, 2006Publication date: February 19, 2009Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, JAPAN STENT TECHNOLOGY CO., LTD.Inventors: Akira Mochizuki, Shuzou Yamashita